Given the extremely poor results of current treatments, many researchers have pursued exploratory strategies. So far, because of the multitudinous morphologic features of the subtypes and the lack of randomized clinical trials, treatment of this disease remains a challenge, especially for R/R-PTCL. A study 3 reported poor survival outcomes for 153 patients with refractory or relapsed PTCL (R/R-PTCL) receiving chemotherapy without hematopoietic transplantation, with a median overall survival (OS) of 13.7 months and progression-free survival (PFS) of 5 months. 2 Furthermore, frequent relapses and initially refractory diseases are not uncommon in PTCL, making it more challenging. 1 The main subtypes are PTCL not otherwise specified, angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma, and natural killer/T-cell lymphoma and are typically treated with conventional regimens for aggressive B-cell lymphomas, resulting in poor clinical outcomes. Peripheral T-cell lymphomas (PTCLs), a rare and heterogeneous group of non-Hodgkin lymphomas, have a dismal prognosis. In the autologous HSCT group, a 3-year OS of 55% (95% CI, 48%-64%) and PFS of 41% (95% CI, 33%-51%), a 5-year OS of 53% (95% CI, 44%-64%) and PFS of 40% (95% CI, 24%-58%), and a 3-year TRM of 7% (95% CI, 2%-23%) were observed.Ĭonclusions and Relevance In this systematic review and meta-analysis, OS and PFS were similar in the allogeneic HSCT and autologous HSCT groups however, allogeneic HSCT was associated with specific survival benefits among patients with R/R-PTCL. Results Of 6548 articles, data extracted from the 30 studies (including 880 patients who underwent allogeneic HSCT and 885 who underwent autologous HSCT) were included in this meta-analysis. Main Outcomes and Measures The prespecified main outcomes were OS, PFS, and TRM. All statistics were pooled by applying a random-effects model. The study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses ( PRISMA) reporting guideline.ĭata Extraction and Synthesis Data on study design, individual characteristics, and outcomes were extracted. Thirty trials were included in the meta-analysis. Study Selection After duplicate and irrelevant publications were discarded, 329 were ineligible according to the inclusion (clinical trials or retrospective studies with >10 samples) and exclusion criteria (articles without overall survival, progression-free survival, and transplantation-related mortality ). Objective To compare the effectiveness and safety of allogeneic HSCT vs autologous HSCT in patients with R/R-PTCL.ĭata Sources A systematic search of the PubMed, Embase, the Cochrane Central Register of Controlled Trials, Wanfang, and China National Knowledge Infrastructure databases with the search items refractory or relapsed peripheral T-cell lymphoma, ASCT/autologous stem-cell transplantation, allo-HSCT/allogeneic stem-cell transplantation, therapeutic effect, and treatment was conducted for articles published from January 12, 2001, to October 1, 2020. Importance Hematopoietic stem cell transplant (HSCT) is an advisable option for refractory or relapsed peripheral T-cell lymphoma (R/R-PTCL), but whether allogeneic HSCT or autologous HSCT is more beneficial is unknown. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |